We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cello Health Plc | LSE:CLL | London | Ordinary Share | GB00B0310763 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 161.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLL
RNS Number : 0545Y
Cello Health PLC
16 August 2018
FOR IMMEDIATE RELEASE 16 August 2018
Cello Health plc
("Cello", the "Company", or the "Group")
Board Changes
Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce the appointment, with immediate effect, of two independent non-executive directors to the Company's board of directors (the "Board"). The new Board members, Clifford Tompsett and Jo LeCouilliard, both have extensive experience in the pharmaceutical industry.
Clifford Tompsett was until recently a senior partner at PriceWaterhouseCoopers LLP ("PwC"), with responsibility for the firm's global cross border IPO practice. For a number of years Clifford led the firm's UK and European activities in the pharmaceutical sector, advising on many of the large deals in the industry. He was at PwC for 38 years, and is a qualified chartered accountant. Clifford will head the Board's Audit Committee and he will also be the Company's Senior Independent Director.
Jo LeCouilliard was until recently at GlaxoSmithKline plc where she held senior executive positions globally with roles in regions including the United States and Asia. Jo has also held senior hospital management positions at BMI Healthcare, and is currently a non-executive director of Circassia Pharmaceuticals plc.
In line with the plans announced at the Annual General Meeting on 10 May 2018, Paul Hamilton and Will David have both stood down as non-executive directors with immediate effect, each having served as members of the Board for more than a decade.
Mark Scott, CEO of Cello, said:
"Both Paul Hamilton and Will David have been non-executive directors of the Company since its formation. Throughout that time, they have helped the Board shape the Group into a leading international business serving predominantly health orientated clients. We are profoundly grateful for their efforts, and wish them both the best for the future.
"I am delighted that the Group has secured the services of two, highly experienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The Board very much looks forward to working with Clifford and Jo as we shape the future growth path for the Group."
Regulatory information
Full name (age) Current directorships: Previous directorships / partnerships (over the last five years): Clifford Peter Tompsett Dundas & Burgun Limited PricewaterhouseCoopers (61) Hatton Farm Estates LLP Limited Kismet Acquisition Limited -------------------------- ------------------------------ Joanna Susan LeCouilliard Circassia Pharmaceuticals GlaxoSmithKline Pte. (54) plc Ltd. Glaxo Wellcome Manufacturing Pte. Ltd. General Healthcare Group Ltd Duke NUS Medical School -------------------------- ------------------------------
Mr. Tompsett and Ms. LeCouilliard do not have any interests in the ordinary shares of the Company.
There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointments of Mr. Tompsett and Ms. LeCouilliard.
Enquiries:
Cello Health plc 020 7812 8460 Mark Scott, Chief Executive Mark Bentley, Group Finance Director Cenkos Securities plc 020 7397 8900 Mark Connelly Harry Hargreaves Buchanan 020 7466 5000 Mark Court Jamie Hooper Sophie Wills
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOAEAAPKFAAPEFF
(END) Dow Jones Newswires
August 16, 2018 08:30 ET (12:30 GMT)
1 Year Cello Health Chart |
1 Month Cello Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions